Halozyme Therapeutics Files 8-K for Material Agreement

TL;DR

HALO signed a big deal on 9/30/25, check the 8-K.

AI Summary

On September 30, 2025, Halozyme Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in San Diego, California, filed an 8-K report detailing this agreement. This filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new contract or partnership for Halozyme Therapeutics, which could impact its future revenue and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks related to partnerships, revenue streams, or operational changes.

Key Players & Entities

• HALOZYME THERAPEUTICS, INC. (company) — Registrant
• September 30, 2025 (date) — Date of Earliest Event Reported
• 12390 El Camino Real, San Diego, California 92130 (address) — Principal Executive Offices
• 001-32335 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Mar
• $750 million — (i) aggregate upfront consideration of $750 million in cash, subject to customary adjustmen
• $50 million — r Consideration ") and (ii) up to three $50 million milestone payments contingent on three
• $36 million — everse termination fee in cash equal to $36 million. The foregoing description of the Mer

Filing Documents

• d807496d8k.htm (8-K) — 35KB
• d807496dex21.htm (EX-2.1) — 626KB
• 0001193125-25-230348.txt ( ) — 921KB
• halo-20250930.xsd (EX-101.SCH) — 3KB
• halo-20250930_lab.xml (EX-101.LAB) — 17KB
• halo-20250930_pre.xml (EX-101.PRE) — 11KB
• d807496d8k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 2.1 Agreement and Plan of Merger, dated as of September 30, 2025, by and among Halozyme Therapeutics, Inc., Erraid Merger Sub Inc., Elektrofi, Inc. and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders as set forth in the Merger Agreement* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Halozyme agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. Certain portions of the exhibit omitted pursuant to Item 601(b)(2) of Regulation S-K. Halozyme agrees to furnish supplementally a copy of an omitted portion to the SEC upon request.

Forward-Looking Statements

Forward-Looking Statements This current report contains "forward-looking statements". All statements, other than statements of historical fact, included herein, including without limitation those regarding Halozyme's acquisition of Elektrofi and the ability of the parties to consummate the Merger on the proposed terms and contemplated timing are, or may be deemed to be, forward-looking statements. Forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "can," "durable," "growth," "innovate," "develop," "vision," "potential," "intends," "estimate," "anticipate," "plan," "predict," "probable," "possible," "should," "continue," and other words of similar meaning and involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, uncertainties concerning future matters such as market conditions, changes in domestic and foreign business changes in the competitive environment in which Halozyme and Elektrofi operate, and financing a potential transaction, inability of the parties to successfully or timely consummate a transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined group or the expected benefits of a transaction, unexpected levels of the combined

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. October 3, 2025 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR